TabRelief, Inc. is seeking $1 million in an angel round convertible note from accredited investors. The note has a two-year maturity date and pays 6% interest. Investors will be able to convert their shares at a 20% discounted conversion price.
TabRelief is developing a medical cannabis brand using its patent-pending effervescent tablet delivery system. The active ingredient is non-psychotropic THCA. This means consumers can maintain their normal routines like working, driving or taking care of loved ones, while remaining focused and alert. The company believes this will expand the $7 billion medical cannabis market to those who value the health and wellness benefits of the plant but do not want the “high.”
TabRelief has organized a professional team including investors and advisers who have demonstrated considerable success in business and in science.
“In five years or less, we see an exit at many multiples of our current valuation,” said co-founder Dean Harris. “Building a strong medical cannabis brand and owning the THCA narrative will increase the worth of our enterprise dramatically. Importantly, we want to do good for our team, our investors and society.”